Literature DB >> 8776820

Efficacy of low-molecular-weight heparin and unfractionated heparin to prevent adhesion of human prostate and bladder carcinoma and melanoma cells to bovine endothelial monolayers. An in vitro study and review of the literature.

C Lersch1, D Gericke, M Classen.   

Abstract

Adherence of human prostate carcinoma (PC 3, DU 145), bladder (647 V, J 82) carcinoma and melanoma (RPMI-8252) cell lines to plastic and bovine endothelial monolayers (BEM) was tested in the presence of 0.5, 1, 5, 10, 20 IU of low-molecular-weight heparin (LMWH), unfractionated heparin (UFH) or saline as a control. Culture medium was supplemented either with 5% fetal calf serum or with human plasma. Floating tumor cells were counted after 2, 4, 24 h of culture in microtiter plates without BEM and after 1.5, 3 and 24 h of culture on BEM. Twenty IU of LMWH increased the numbers of bladder carcinoma cells adhering to BEM as did 20 IU of UFH in cultures of DU 145 prostate carcinoma and RPMI-8252 melanoma cells. LMWH obviously does not prevent human prostate and bladder carcinoma and melanoma cells from adhering to BEM more effectively than UFH. The in vivo effect of UFH and perhaps also LMWH that hinders intravenous tumor cell colonization in blood vessels obviously does not depend on the interaction with endothelial cells alone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8776820     DOI: 10.1159/000282848

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  2 in total

1.  The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer.

Authors:  Jong Chul Park; Caroline F Pratz; Anteneh Tesfaye; Robert A Brodsky; Emmanuel S Antonarakis
Journal:  Clin Genitourin Cancer       Date:  2014-06-11       Impact factor: 2.872

2.  Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study.

Authors:  Saroj Niraula; Greg Pond; Ronald de Wit; Mario Eisenberger; Ian F Tannock; Anthony M Joshua
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.